Literature DB >> 18558942

Activity of ciprofloxacin and levofloxacin in experimental pneumonia caused by Klebsiella pneumoniae deficient in porins, expressing active efflux and producing QnrA1.

J M Rodríguez-Martínez1, C Pichardo, I García, M E Pachón-Ibañez, F Docobo-Pérez, A Pascual, J Pachón, L Martínez-Martínez.   

Abstract

The objective of this study was to evaluate the activities of ciprofloxacin and levofloxacin in a murine model of pneumonia caused by Klebsiella pneumoniae C2 (with altered GyrA, deficient in porins and expressing active efflux of quinolones) and the transconjugant C2pMG252 derived from it and expressing the qnrA1 determinant. MICs and MBCs of the two quinolones were determined according to CLSI guidelines. Time-kill curves (at 1x and 4x MIC) were also performed to assess bactericidal activity. An experimental model of pneumonia in mice was evaluated. Groups of 15 mice were infected with either strain and treated with ciprofloxacin (80 mg/kg/day) or levofloxacin (100 mg/kg/day). Control non-treated animals were also evaluated. In the case of strain C2, log(10) CFU/g of lung in non-treated animals was 9.16 +/- 2.16. This value was reduced to 3.53 +/- 1.04 (p <0.001) and 3.38 +/- 0.46 (p <0.001) in animals treated with ciprofloxacin or levofloxacin, respectively. Percentages of surviving mice were 26.7% (control group) and 100% (both ciprofloxacin and levofloxacin; p <0.001 vs. controls). Bacterial counts (log(10) CFU/g) in lungs of animals infected with strain C2pMG252 were 9.65 +/- 2.49 in non-treated animals and 7.74 +/- 2.67 and 7.57 +/- 3.84 for those treated with ciprofloxacin or levofloxacin, respectively (p >0.05 vs. control group). Of non-treated animals infected with strain C2pMG252, 14.3% survived. Ciprofloxacin and levofloxacin improved the survival in these mice (53.3% for both antimicrobials, p 0.03). In conclusion, the expression of qnrA1 in K. pneumoniae with additional mechanisms of resistance causes decreased efficacy of fluoroquinolones in a pneumonia model in mice.

Entities:  

Mesh:

Substances:

Year:  2008        PMID: 18558942     DOI: 10.1111/j.1469-0691.2008.02020.x

Source DB:  PubMed          Journal:  Clin Microbiol Infect        ISSN: 1198-743X            Impact factor:   8.067


  15 in total

Review 1.  Efflux-mediated drug resistance in bacteria: an update.

Authors:  Xian-Zhi Li; Hiroshi Nikaido
Journal:  Drugs       Date:  2009-08-20       Impact factor: 9.546

Review 2.  Plasmid-mediated quinolone resistance.

Authors:  George A Jacoby; Jacob Strahilevitz; David C Hooper
Journal:  Microbiol Spectr       Date:  2014-10

3.  Updated Multiplex PCR for Detection of All Six Plasmid-Mediated qnr Gene Families.

Authors:  Gabriela Bergiante Kraychete; Larissa Alvarenga Batista Botelho; Eloiza Helena Campana; Renata Cristina Picão; Raquel Regina Bonelli
Journal:  Antimicrob Agents Chemother       Date:  2016-11-21       Impact factor: 5.191

4.  Ciprofloxacin treatment failure in a murine model of pyelonephritis due to an AAC(6')-Ib-cr-producing Escherichia coli strain susceptible to ciprofloxacin in vitro.

Authors:  T Guillard; E Cambau; F Chau; L Massias; C de Champs; B Fantin
Journal:  Antimicrob Agents Chemother       Date:  2013-09-09       Impact factor: 5.191

5.  In vitro effect of qnrA1, qnrB1, and qnrS1 genes on fluoroquinolone activity against isogenic Escherichia coli isolates with mutations in gyrA and parC.

Authors:  A Briales; J M Rodríguez-Martínez; C Velasco; P Díaz de Alba; J Domínguez-Herrera; J Pachón; A Pascual
Journal:  Antimicrob Agents Chemother       Date:  2010-12-20       Impact factor: 5.191

Review 6.  Treatment of Infections Caused by Extended-Spectrum-Beta-Lactamase-, AmpC-, and Carbapenemase-Producing Enterobacteriaceae.

Authors:  Jesús Rodríguez-Baño; Belén Gutiérrez-Gutiérrez; Isabel Machuca; Alvaro Pascual
Journal:  Clin Microbiol Rev       Date:  2018-02-14       Impact factor: 26.132

Review 7.  Topoisomerase Inhibitors: Fluoroquinolone Mechanisms of Action and Resistance.

Authors:  David C Hooper; George A Jacoby
Journal:  Cold Spring Harb Perspect Med       Date:  2016-09-01       Impact factor: 6.915

8.  Impact of low-level resistance to fluoroquinolones due to qnrA1 and qnrS1 genes or a gyrA mutation on ciprofloxacin bactericidal activity in a murine model of Escherichia coli urinary tract infection.

Authors:  Nicolas Allou; Emmanuelle Cambau; Laurent Massias; Françoise Chau; Bruno Fantin
Journal:  Antimicrob Agents Chemother       Date:  2009-07-27       Impact factor: 5.191

Review 9.  Plasmid-mediated quinolone resistance: a multifaceted threat.

Authors:  Jacob Strahilevitz; George A Jacoby; David C Hooper; Ari Robicsek
Journal:  Clin Microbiol Rev       Date:  2009-10       Impact factor: 26.132

10.  Plasmidic qnrA3 enhances Escherichia coli fitness in absence of antibiotic exposure.

Authors:  Adrien Michon; Nicolas Allou; Françoise Chau; Isabelle Podglajen; Bruno Fantin; Emmanuelle Cambau
Journal:  PLoS One       Date:  2011-09-07       Impact factor: 3.240

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.